The interactions between insulin and androgens in progression to castrate-resistant prostate cancer

Advances in Urology

Volumn , Issue , 2012, Pages

  Gunter, Jennifer H ^a   Lubik, Amy A ^a   McKenzie, Ian ^a   Pollak, Michael ^b   Nelson, Colleen C ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861081470     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/248607     Document Type: Review

References (141)

1. Grundy S. M., Brewer H. B., Cleeman J. I., Smith S. C., Lenfant C., Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition Circulation 2004 109 3 433 438 (Pubitemid 38133916)
2. Hammarsten J., Hgstedt B., Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer European Journal of Cancer 2005 41 18 2887 2895 (Pubitemid 41713128)
3. Hammarsten J., Peeker R., Urological aspects of the metabolic syndrome Nature Reviews Urology 2011 8 9 483 494
4. Park J., Euhus D. M., Scherer P. E., Paracrine and endocrine effects of adipose tissue on cancer development and progression Endocrine Reviews 2011 32 4 550 570
5. Hsing A., Sakoda L., Chua S. J., Obesity, metabolic syndrome, and prostate cancer The American Journal of Clinical Nutrition 2007 86 3 843S 857S
6. Ma J., Li H., Giovannucci E., Mucci L., Qiu W., Nguyen P. L., Gaziano J. M., Pollak M., Stampfer M. J., Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis The Lancet Oncology 2008 9 11 1039 1047
7. Jayachandran J., Aronson W. J., Terris M. K., Presti J. C., Amling C. L., Kane C. J., Freedland S. J., Obesity and positive surgical margins by anatomic location after radical prostatectomy: results from the shared equal access regional cancer hospital database BJU International 2008 102 8 964 968
8. Rodriguez C., Patel A. V., Calle E. E., Jacobs E. J., Chao A., Thun M. J., Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States Cancer Epidemiology Biomarkers and Prevention 2001 10 4 345 353 (Pubitemid 32703219)
9. Fowke J. H., Matthews C. M., Buchowski M. S., Signorello L. B., Chang S. S., Cookson M. S., Blot W. J., Association between prostate-specific antigen and leptin, adiponectin, HbA1c or C-peptide among African-American and Caucasian men Prostate Cancer and Prostatic Diseases 2008 11 3 264 269
10. Porter M. P., Stanford J. L., Obesity and the risk of prostate cancer Prostate 2005 62 4 316 321 (Pubitemid 40224137)
11. Mondul A. M., Weinstein S. J., Virtamo J., Albanes D., Serum total and HDL cholesterol and risk of prostate cancer Cancer Causes and Control 2011 22 11 1545 1552
12. Van Hemelrijck M., Garmo H., Holmberg L., Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose Cancer 2011 117 10 2086 2095
13. Van Hemelrijck M., Walldius G., Jungner I., Hammar N., Garmo H., Binda E., Hayday A., Lambe M., Holmberg L., Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study Cancer Causes and Control 2011 22 7 1011 1019
14. Murtola T. J., Syvl H., Pennanen P., Bluer M., Solakivi T., Ylikomi T., Tammela T. L., Comparative effects of high and low-dose simvastatin on prostate epithelial cells: the role of LDL European Journal of Pharmacology 2011 673 13 96 100
15. Das U. N., Essential fatty acids enhance free radical generation and lipid peroxidation to induce apoptosis of tumor cells Clinical Lipidology 2011 6 4 463 489
16. Nomura D. K., Lombardi D. P., Chang J. W., Niessen S., Ward A. M., Long J. Z., Hoover H. H., Cravatt B. F., Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer Chemistry and Biology 2011 18 7 846 856
17. Brasky T. M., Till C., White E., Neuhouser M. L., Song X., Goodman P., Thompson I. M., King I. B., Albanes D., Kristal A. R., Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial American Journal of Epidemiology 2011 173 12 1429 1439
18. Cavazos D. A., Price R. S., Apte S. S., deGraffenried L. A., Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF- B Prostate 2011 71 13 1420 1428
19. Andersson S. O., Wolk A., Bergstrm R., Adami H. O., Engholm G., Englund A., Nyrén O., Body size and prostate cancer: a 20-year follow-up study among 135 006 Swedish construction workers Journal of the National Cancer Institute 1997 89 5 385 389 (Pubitemid 27102604)
20. Hsing A. W., Sakoda L. C., Chua S. Jr., Obesity, metabolic syndrome, and prostate cancer The American Journal of Clinical Nutrition 2007 86 3 s843 857
21. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia Nature Reviews Cancer 2008 8 12 915 928
22. Renehan A. G., Frystyk J., Flyvbjerg A., Obesity and cancer risk: the role of the insulin-IGF axis Trends in Endocrinology and Metabolism 2006 17 8 328 336 (Pubitemid 44397568)
23. Dandona P., Dhindsa S., Chaudhuri A., Bhatia V., Topiwala S., Mohanty P., Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome Current Molecular Medicine 2008 8 8 816 828
24. Haffner S. M., Valdez R. A., Mykkanen L., Stern M. P., Katz M. S., Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men Metabolism 1994 43 5 599 603 (Pubitemid 24145467)
25. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssnen K., Tuomainen T. P., Salonen R., Rauramaa R., Salonen J. T., Sex hormones, inflammation and the metabolic syndrome: a population-based study European Journal of Endocrinology 2003 149 6 601 608 (Pubitemid 38054707)
26. Rohrmann S., Shiels M. S., Lopez D. S., Rifai N., Nelson W. G., Kanarek N., Guallar E., Menke A., Joshu C. E., Feinleib M., Sutcliffe S., Platz E. A., Body fatness and sex steroid hormone concentrations in US men: results from NHANES III Cancer Causes and Control 2011 22 8 1141 1151
27. Corrales J. J., Burgo R. M., Garca-Berrocal B., Almeida M., Alberca I., Gonzlez-Buitrago J. M., Orfao A., Miralles J. M., Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control Metabolism 2004 53 5 666 672 (Pubitemid 38596543)
28. Moriarty-Kelsey M., Harwood J. E., Travers S. H., Zeitler P. S., Nadeau K. J., Testosterone, obesity and insulin resistance in young males: evidence for an association between gonadal dysfunction and insulin resistance during puberty Journal of Pediatric Endocrinology and Metabolism 2010 23 12 1281 1287
29. Wang C., Feng R., Sun D., Li Y., Bi X., Sun C., Metabolic profiling of urine in young obese men using ultra performance liquid chromatography and Q-TOF mass spectrometry (UPLC/Q-TOF MS) Journal of Chromatography B 2011 879 27 2871 2876
30. A. I. O. H. A. W. A. A. O. C., Cancer in Australia: An Overview, 2010 2010 60 Canberra, Australia AIHW Australian Institute of Health and Welfares Cancer Series
31. Howlader N. A., Noone A. M., Krapcho M., SEER Cancer Statistics Review, 1975-2008 2010 Bethesda, Md, USA National Cancer Institute
32. Rashid M. H., Chaudhary U. B., Intermittent androgen deprivation therapy for prostate cancer Oncologist 2004 9 3 295 301 (Pubitemid 38756877)
33. Denmeade S. R., Isaacs J. T., A history of prostate cancer treatment Nature Reviews Cancer 2002 2 5 389 396 (Pubitemid 37328952)
34. Scher H. I., Sawyers C. L., Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis Journal of Clinical Oncology 2005 23 32 8253 8261 (Pubitemid 46211563)
35. So A., Gleave M., Hurtado-Col A., Nelson C., Mechanisms of the development of androgen independence in prostate cancer World Journal of Urology 2005 23 1 1 9 (Pubitemid 40425164)
36. Stanbrough M., Bubley G. J., Ross K., Golub T. R., Rubin M. A., Penning T. M., Febbo P. G., Balk S. P., Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Research 2006 66 5 2815 2825
37. Montgomery R. B., Mostaghel E. A., Vessella R., Hess D. L., Kalhorn T. F., Higano C. S., True L. D., Nelson P. S., Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Research 2008 68 11 4447 4454
38. Steinkamp M. P., O'Mahony O. A., Brogley M., Rehman H., LaPensee E. W., Dhanasekaran S., Hofer M. D., Kuefer R., Chinnaiyan A., Rubin M. A., Pienta K. J., Robins D. M., Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy Cancer Research 2009 69 10 4434 4442
39. Mostaghel E. A., Page S. T., Lin D. W., Fazli L., Coleman I. M., True L. D., Knudsen B., Hess D. L., Nelson C. C., Matsumoto A. M., Bremner W. J., Gleave M. E., Nelson P. S., Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer Cancer Research 2007 67 10 5033 5041 (Pubitemid 46910214)
40. Locke J. A., Guns E. S., Lubik A. A., Adomat H. H., Hendy S. C., Wood C. A., Ettinger S. L., Gleave M. E., Nelson C. C., Androgen Levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Research 2008 68 15 6407 6415
41. Leon C. G., Locke J. A., Adomat H. H., Etinger S. L., Twiddy A. L., Neumann R. D., Nelson C. C., Guns E. S., Wasan K. M., Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model Prostate 2010 70 4 390 400
42. Petrylak D. P., Tangen C. M., Hussain M. H. A., Lara P. N., Jones J. A., Taplin M. E., Burch P. A., Berry D., Moinpour C., Kohli M., Benson M. C., Small E. J., Raghavan D., Crawford E. D., Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer The New England Journal of Medicine 2004 351 15 1513 1520 (Pubitemid 39315318)
43. Attard G., Reid A. H. M., A'Hern R., Parker C., Oommen N. B., Folkerd E., Messiou C., Molife L. R., Maier G., Thompson E., Olmos D., Sinha R., Lee G., Dowsett M., Kaye S. B., Dearnaley D., Kheoh T., Molina A., De Bono J. S., Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer Journal of Clinical Oncology 2009 27 23 3742 3748
44. de Bono J. S., Logothetis C. J., Molina A., Fizazi K., North S., Chu L., Chi K. N., Jones R. J., Goodman O. B. Jr., Saad F., Staffurth J. N., Mainwaring P., Harland S., Flaig T. W., Hutson T. E., Cheng T., Patterson H., Hainsworth J. D., Ryan C. J., Sternberg C. N., Ellard S. L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C. M., Scher H. I., Abiraterone and increased survival in metastatic prostate cancer The New England Journal of Medicine 2011 364 21 1995 2005
45. Mostaghel E. A., Marck B. T., Plymate S. R., Vessella R. L., Balk S., Matsumoto A. M., Nelson P. S., Montgomery R. B., Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clinical Cancer Research 2011 17 18 5913 5925
46. Faris J. E., Smith M. R., Metabolic sequelae associated with androgen deprivation therapy for prostate cancer Current Opinion in Endocrinology, Diabetes and Obesity 2010 17 3 240 246
47. Smith M. R., Lee H., Nathan D. M., Insulin sensitivity during combined androgen blockade for prostate cancer Journal of Clinical Endocrinology and Metabolism 2006 91 4 1305 1308
48. Basaria S., Muller D. C., Carducci M. A., Egan J., Dobs A. S., Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy Cancer 2006 106 3 581 588 (Pubitemid 43157621)
49. Freedland S. J., Aronson W. J., Obesity and prostate cancer Urology 2005 65 3 433 439 (Pubitemid 40385983)
50. Buschemeyer W. C. III, Freedland S. J., Obesity and prostate cancer: epidemiology and clinical implications European Urology 2007 52 2 331 343 (Pubitemid 46963472)
51. Cox M. E., Gleave M. E., Zakikhani M., Bell R. H., Piura E., Vickers E., Cunningham M., Larsson O., Fazli L., Pollak M., Insulin receptor expression by human prostate cancers Prostate 2009 69 1 33 40
52. Isbarn H., Boccon-Gibod L., Carroll P. R., Montorsi F., Schulman C., Smith M. R., Sternberg C. N., Studer U. E., Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks European Urology 2009 55 1 62 75
53. Hammarsten J., Hgstedt B., Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer European Journal of Cancer 2005 41 18 2887 2895 (Pubitemid 41713128)
54. Neuhouser M. L., Till C., Kristal A., Goodman P., Hoque A., Platz E. A., Hsing A. W., Albanes D., Parnes H. L., Pollak M., Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial Cancer Prevention Research 2010 3 3 279 289
55. Simon D., Preziosi P., Barrett-Connor E., Roger M., Saint-Paul M., Nahoul K., Papoz L., Interrelation between plasma testosterone and plasma insulin in healthy adult men: the telecom study Diabetologia 1992 35 2 173 177
56. Giganti M. G., Minella D., Testa B., Zenobi R., Biancolella M., Isidori A. M., Caprio M., Novelli G., Fabbri A., A pilot study on the transcriptional response of androgen- and insulin-related genes in peripheral blood mononuclear cells induced by testosterone administration in hypogonadal men Journal of Biological Regulators and Homeostatic Agents 2011 25 2 291 294
57. Dandona P., Dhindsa S., Update: hypogonadotropic hypogonadism in type 2 diabetes and obesity Journal of Clinical Endocrinology and Metabolism 2011 96 9 2643 2651
58. Laaksonen D. E., Niskanen L., Punnonen K., Nyyssnen K., Tuomainen T. P., Valkonen V. P., Salonen R., Salonen J. T., Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men Diabetes Care 2004 27 5 1036 1041 (Pubitemid 38579762)
59. Biswas M., Hampton D., Newcombe R. G., Rees D. A., Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of lifea. Clinical Endocrinology. In press
60. Grossmann M., Thomas M. C., Panagiotopoulos S., Sharpe K., MacIsaac R. J., Clarke S., Zajac J. D., Jerums G., Low testosterone levels are common and associated with insulin resistance in men with diabetes Journal of Clinical Endocrinology and Metabolism 2008 93 5 1834 1840 (Pubitemid 351656526)
61. Halmenschlager G., Rhoden E. L., Riedner C. E., The influence of age on bioavailable and free testosterone is independent of body mass index and glucose levels World Journal of Urology 2011 29 4 541 546
62. Dhindsa S., Prabhakar S., Sethi M., Bandyopadhyay A., Chaudhuri A., Dandona P., Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes Journal of Clinical Endocrinology and Metabolism 2004 89 11 5462 5468 (Pubitemid 39518427)
63. He X. X., Tu S. M., Lee M. H., Yeung S. C., Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients Annals of Oncology 2011 22 12 2640 2645
64. Pitteloud N., Mootha V. K., Dwyer A. A., Hardin M., Lee H., Eriksson K. F., Tripathy D., Yialamas M., Groop L., Elahi D., Hayes F. J., Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men Diabetes Care 2005 28 7 1636 1642 (Pubitemid 41340902)
65. Cohen P. G., Obesity in men: the hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis Medical Hypotheses 2008 70 2 358 360 (Pubitemid 350297595)
66. Vermeulen A., Kaufman J. M., Deslypere J. P., Thomas G., Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma androgens in hypogonadism of obese men Journal of Clinical Endocrinology and Metabolism 1993 76 5 1140 1146 (Pubitemid 23155426)
67. Dhindsa S., Furlanetto R., Vora M., Low estradiol concentrations in men with subnormal testosterone concentrations and type 2 diabetes Diabetes Care 2011 34 8 1854 1859
68. Tajar A., Forti G., O'Neill T. W., Lee D. M., Silman A. J., Finn J. D., Bartfai G., Boonen S., Casanueva F. F., Giwercman A., Han T. S., Kula K., Labrie F., Lean M. E. J., Pendleton N., Punab M., Vanderschueren D., Huhtaniemi I. T., Wu F. C. W., Petrone L., Corona G., Borghs H., Slowikowska-Hilczer J., Walczak-Jedrzejowska R., Steer P., Pye S., Lage M., Fldesi I., Fejes I., Korrovitz P., Jiang M., Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study Journal of Clinical Endocrinology and Metabolism 2010 95 4 1810 1818
69. Tomaszewska-Zaremba D., Herman A., The role of immunological system in the regulation of gonadoliberin and gonadotropin secretion Reproductive Biology 2009 9 1 11 23
70. Watanobe H., Hayakawa Y., Hypothalamic interleukin-1 and tumor necrosis factor-, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats Endocrinology 2003 144 11 4868 4875 (Pubitemid 37378401)
71. Rubinow K., Snyder C. N., Amory J. K., Hoofnagle A. N., Page S. T., Acute testosterone deprivation reduces insulin sensitivity in men Clinical Endocrinology 2012 76 2 281 288
72. Smith M. R., Lee H., Fallon M. A., Nathan D. M., Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer Urology 2008 71 2 318 322 (Pubitemid 351282338)
73. Gautron L., Elmquist J. K., Sixteen years and counting: an update on leptin in energy balance Journal of Clinical Investigation 2011 121 6 2087 2093
74. Whitehead J. P., Richards A. A., Hickman I. J., Macdonald G. A., Prins J. B., Adiponectina key adipokine in the metabolic syndrome Diabetes, Obesity and Metabolism 2006 8 3 264 280
75. Kalinchenko S. Y., Tishova Y. A., Mskhalaya G. J., Gooren L. J. G., Giltay E. J., Saad F., Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study Clinical Endocrinology 2010 73 5 602 612
76. Nishizawa H., Shimomura L., Kishida K., Maeda N., Kuriyama H., Nagaretani H., Matsuda M., Kondo H., Furuyama N., Kihara S., Nakamura T., Tochino Y., Funahashi T., Matsuzawa Y., Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein Diabetes 2002 51 9 2734 2741 (Pubitemid 34970926)
77. Page S. T., Herbst K. L., Amory J. K., Coviello A. D., Anawalt B. D., Matsumoto A. M., Bremner W. J., Testosterone administration suppresses adiponectin levels in men Journal of Andrology 2005 26 1 85 92 (Pubitemid 39665280)
78. Yialamas M. A., Dwyer A. A., Hanley E., Lee H., Pitteloud N., Hayes F. J., Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism Journal of Clinical Endocrinology and Metabolism 2007 92 11 4254 4259 (Pubitemid 350074740)
79. Yannucci J., Manola J., Garnick M. B., Bhat G., Bubley G. J., The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters Journal of Urology 2006 176 2 520 525 (Pubitemid 43927931)
80. Flanagan J., Gray P. K., Hahn N., Hayes J., Myers L. J., Carney-Doebbeling C., Sweeney C. J., Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer Annals of Oncology 2011 22 4 801 807
81. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R., Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease Endocrine Reviews 2009 30 6 586 623
82. Mounier C., Posner B. I., Transcriptional regulation by insulin: from the receptor to the gene Canadian Journal of Physiology and Pharmacology 2006 84 7 713 724 (Pubitemid 44897892)
83. Milazzo G., Yip C. C., Maddux B. A., Vigneri R., Goldfine I. D., High-affinity insulin binding to an atypical insulin-like growth factor-I receptor in human breast cancer cells Journal of Clinical Investigation 1992 89 3 899 908
84. Ulanet D. B., Ludwig D. L., Kahn C. R., Hanahan D., Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy Proceedings of the National Academy of Sciences of the United States of America 2010 107 24 10791 10798
85. Zhang H., Fagan D. H., Zeng X., Freeman K. T., Sachdev D., Yee D., Inhibition of cancer cell proliferation and metastasis by insulin receptor downregulation Oncogene 2010 29 17 2517 2527
86. Culig Z., Androgen receptor cross-talk with cell signalling pathways Growth Factors 2004 22 3 179 184 (Pubitemid 39377910)
87. Grisouard J., Mayer D., Specific involvement of glycogen synthase kinase-3 in the function and activity of sex steroid hormone receptors reveals the complexity of their regulation Journal of Steroid Biochemistry and Molecular Biology 2009 117 4-5 87 92
88. Rana K., Fam B. C., Clarke M. V., Pang T. P.S., Zajac J. D., MacLean H. E., Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance American Journal of Physiology 2011 301 5 E767 E778
89. Zitzmann M., Gromoll J., Von Eckardstein A., Nieschlag E., The CAG repeat polymorphism in the androgen receptor gene modulates body fat mass and serum concentrations of leptin and insulin in men Diabetologia 2003 46 1 31 39 (Pubitemid 36237744)
90. Singh R., Artaza J. N., Taylor W. E., Braga M., Yuan X., Gonzalez-Cadavid N. F., Bhasin S., Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with -catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors Endocrinology 2006 147 1 141 154 (Pubitemid 43004269)
91. Handschin C., Spiegelman B. M., The role of exercise and PGC1 in inflammation and chronic disease Nature 2008 454 7203 463 469
92. Mori S., Chang J. T., Andrechek E. R., Matsumura N., Baba T., Yao G., Kim J. W., Gatza M., Murphy S., Nevins J. R., Anchorage-independent cell growth signature identifies tumors with metastatic potential Oncogene 2009 28 31 2796 2805
93. Carver B., Chapinski C., Wongvipat J., Hieronymus H., Chen Y., Chandarlapaty S., Arora V., Le C., Koutcher J., Scher H., Scardino P., Rosen N., Sawyers C., Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 2011 19 5 575 586
94. Kaarb M., Mikkelsen O. L., Malerd L., Qu S., Lobert V. H., Akgul G., Halvorsen T., Mlandsmo G. M., Saatcioglu F., PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells Cellular Oncology 2010 32 1-2 11 27
95. Mulholland D., Tran L., Li Y., Cai H., Morim A., Wang S., Plaisier S., Garraway I., Huang J., Graeber T., Wu H., Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth Cancer Cell 2011 19 6 792 804
96. Xin L., Teitell M. A., Lawson D. A., Kwon A., Mellinghoff I. K., Witte O. N., Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor Proceedings of the National Academy of Sciences of the United States of America 2006 103 20 7789 7794
97. Courtney K. D., Corcoran R. B., Engelman J. A., The PI3K pathway as drug target in human cancer Journal of Clinical Oncology 2010 28 6 1075 1083
98. El Sheikh S. S., Romanska H. M., Abel P., Domin J., Lalani E. N., Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancera pilot study Neoplasia 2008 10 9 949 953
99. Reid A. H., Attard G., Ambroisine L., Fisher G., Kovacs G., Brewer D., Clark J., Flohr P., Edwards S., Berney D. M., Foster C. S., Fletcher A., Gerald W. L., Mller H., Reuter V. E., Scardino P. T., Cuzick J., De Bono J. S., Cooper C. S., Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer British Journal of Cancer 2010 102 4 678 684
100. Taylor B. S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B. S., Arora V. K., Kaushik P., Cerami E., Reva B., Antipin Y., Mitsiades N., Landers T., Dolgalev I., Major J. E., Wilson M., Socci N. D., Lash A. E., Heguy A., Eastham J. A., Scher H. I., Reuter V. E., Scardino P. T., Sander C., Sawyers C. L., Gerald W. L., Integrative genomic profiling of human prostate cancer Cancer Cell 2010 18 1 11 22
101. Call R., Grimsley M., Cadwallader L., Cialone L., Hill M., Hreish V., King S. T., Riche D. M., Insulin-carcinogen or mitogen? Preclinical and clinical evidence from prostate, breast, pancreatic, and colorectal cancer research Postgraduate Medicine 2010 122 3 158 165
102. Simon D., Balkau B., Diabetes mellitus, hyperglycaemia and cancer Diabetes and Metabolism 2010 36 3 182 191
103. Fukui M., Tanaka M., Kadono M., Imai S., Hasegawa G., Yoshikawa T., Nakamura N., Serum prostate-specific antigen levels in men with type 2 diabetes Diabetes Care 2008 31 5 930 931
104. Abdollah F., Briganti A., Suardi N., Gallina A., Capitanio U., Salonia A., Cestari A., Guazzoni G., Rigatti P., Montorsi F., Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer and Prostatic Diseases 2011 14 1 74 78
105. Pierce B. L., Plymate S., Ostrander E. A., Stanford J. L., Diabetes mellitus and prostate cancer risk The Prostate 2008 68 10 1126 1132 (Pubitemid 351875184)
106. Algire C., Amrein L., Zakikhani M., Panasci L., Pollak M., Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase Endocrine-Related Cancer 2010 17 2 351 360
107. Sahra I. B., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J. F., Le Marchand-Brustel Y., Bost F., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 2008 27 25 3576 3586 (Pubitemid 351793803)
108. Currie C. J., Poole C. D., Gale E. A., The influence of glucose-lowering therapies on cancer risk in type 2 diabetes Diabetologia 2009 52 9 1766 1777
109. DeCensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S., Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prevention Research 2010 3 11 1451 1461
110. Wright J. L., Stanford J. L., Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study Cancer Causes and Control 2009 20 9 1617 1622
111. Libby G., Donnelly L. A., Donnan P. T., Alessi D. R., Morris A. D., Evans J. M. M., New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes Diabetes Care 2009 32 9 1620 1625
112. Evans J. M., Donnelly L. A., Emslie-Smith A. M., Alessi D. R., Morris A. D., Metformin and reduced risk of cancer in diabetic patients British Medical Journal 2005 330 7503 1304 1305 (Pubitemid 40813563)
113. Azoulay L., Dell'Aniello S., Gagnon B., Pollak M., Suissa S., Metformin and the incidence of prostate cancer in patients with type 2 diabetes Cancer Epidemiology Biomarkers and Prevention 2011 20 2 337 344
114. Hadad S. M., Fleming S., Thompson A. M., Targeting AMPK: a new therapeutic opportunity in breast cancer Critical Reviews in Oncology/Hematology 2008 67 1 1 7
115. Pollak M., Metformin and other biguanides in oncology: advancing the research agenda Cancer Prevention Research 2010 3 9 1060 1065
116. Dowling R. J., Zakikhani M., Fantus I. G., Pollak M., Sonenberg N., Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Research 2007 67 22 10804 10812 (Pubitemid 350145909)
117. Green A. S., Chapuis N., Maciel T. T., Willems L., Lambert M., Arnoult C., Boyer O., Bardet V., Park S., Foretz M., Viollet B., Ifrah N., Dreyfus F., Hermine O., Moura I. C., Lacombe C., Mayeux P., Bouscary D., Tamburini J., The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation Blood 2010 116 20 4262 4273
118. Tao R., Gong J., Luo X., Zang M., Guo W., Wen R., Luo Z., AMPK exerts dual regulatory effects on the PI3K pathway Journal of Molecular Signaling 2010 5 1 1
119. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M. F., Goodyear L. J., Moller D. E., Role of AMP-activated protein kinase in mechanism of metformin action Journal of Clinical Investigation 2001 108 8 1167 1174 (Pubitemid 32995375)
120. Hardie D. G., AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy Nature Reviews Molecular Cell Biology 2007 8 10 774 785 (Pubitemid 47462132)
121. Zadra G., Priolo C., Patnaik A., Loda M., New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK Clinical Cancer Research 2010 16 13 3322 3328
122. Frigo D. E., Howe M. K., Wittmann B. M., Brunner A. M., Cushman I., Wang Q., Brown M., Means A. R., McDonnell D. P., CaM kinase kinase -mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells Cancer Research 2011 71 2 528 537
123. Massie C. E., Lynch A., Ramos-Montoya A., Boren J., Stark R., Fazli L., Warren A., Scott H., Madhu B., Sharma N., Bon H., Zecchini V., Smith D. -M., Denicola G. M., Mathews N., Osborne M., Hadfield J., MacArthur S., Adryan B., Lyons S. K., Brindle K. M., Griffiths J., Gleave M. E., Rennie P. S., Neal D. E., Mills I. G., The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis The EMBO Journal 2011 30 13 2719 2733
124. Anderson K. A., Ribar T. J., Lin F., Noeldner P. K., Green M. F., Muehlbauer M. J., Witters L. A., Kemp B. E., Means A. R., Hypothalamic CaMKK2 contributes to the regulation of energy balance Cell Metabolism 2008 7 5 377 388 (Pubitemid 351598022)
125. Jaffe A. B., Hall A., Rho GTPases: biochemistry and biology Annual Review of Cell and Developmental Biology 2005 21 247 269 (Pubitemid 41740635)
126. Shaw R. J., Bardeesy N., Manning B. D., Lopez L., Kosmatka M., DePinho R. A., Cantley L. C., The LKB1 tumor suppressor negatively regulates mTOR signaling Cancer Cell 2004 6 1 91 99 (Pubitemid 38903165)
127. Xiang X., Saha A. K., Wen R., Ruderman N. B., Luo Z., AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms Biochemical and Biophysical Research Communications 2004 321 1 161 167 (Pubitemid 39055618)
128. Zhou J., Huang W., Tao R., Ibaragi S., Lan F., Ido Y., Wu X., Alekseyev Y. O., Lenburg M. E., Hu G. F., Luo Z., Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells Oncogene 2009 28 18 1993 2002
129. Minokoshi Y., Kim Y. B., Peroni O. D., Fryer L. G. D., Mller C., Carling D., Kahn B. B., Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase Nature 2002 415 6869 339 343 (Pubitemid 34087557)
130. Liu Y., Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer Prostate Cancer and Prostatic Diseases 2006 9 3 230 234 (Pubitemid 44317255)
131. Gregory C. W., Johnson R. T., Mohler J. L., French F. S., Wilson E. M., Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen Cancer Research 2001 61 7 2892 2898 (Pubitemid 32691931)
132. Titus M. A., Schell M. J., Lih F. B., Tomer K. B., Mohler J. L., Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clinical Cancer Research 2005 11 13 4653 4657 (Pubitemid 41557182)
133. Munir I., Yen H. W., Geller D. H., Torbati D., Bierden R. M., Weitsman S. R., Agarwal S. K., Magoffin D. A., Insulin augmentation of 17 -hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells Endocrinology 2004 145
134. Seto-Young D., Avtanski D., Strizhevsky M., Parikh G., Patel P., Kaplun J., Holcomb K., Rosenwaks Z., Poretsky L., Interactions among peroxisome proliferator activated receptor-, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells Journal of Clinical Endocrinology and Metabolism 2007 92 6 2232 2239 (Pubitemid 46997128)
135. Nestler J. E., Insulin regulation of human ovarian androgens Human Reproduction 1997 12 supplement 1 53 62
136. Lubik A. A., Gunter J. H., Hendy S. C., Locke J. A., Adomat H. H., Thompson V., Herington A., Gleave M. E., Pollak M., Nelson C. C., Insulin increases de novo steroidogenesis in prostate cancer cells Cancer Research 2011 71 17 5754 5764
137. Zoubeidi A., Ettinger S., Beraldi E., Hadaschik B., Zardan A., Klomp L. W. J., Nelson C. C., Rennie P. S., Gleave M. E., Clusterin facilitates COMMD1 and I- B degradation to enhance NF- B activity in prostate cancer cells Molecular Cancer Research 2010 8 1 119 130
138. Cochrane D. R., Wang Z., Muramaki M., Gleave M. E., Nelson C. C., Differential regulation of clusterin and its isoforms by androgens in prostate cells Journal of Biological Chemistry 2007 282 4 2278 2287 (Pubitemid 47076744)
139. Zoubeidi A., Zardan A., Beraldi E., Fazli L., Sowery R., Rennie P., Nelson C., Gleave M. E., Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity Cancer Research 2007 67 21 10455 10465 (Pubitemid 350070821)
140. Zoubeidi A., Zardan A., Wiedmann R. M., Locke J., Beraldi E., Fazli L., Gleave M. E., Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD Cancer Research 2010 70 6 2307 2317
141. Redig A. J., Munshi H. G., Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy American Journal of Medicine 2010 123 1 87.e1 87.e6